Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by ...
Dear Dr. Roach: Recently, I almost experienced kidney failure from a probable infection. I am a male, age 68. My glomerular filtration rate (GFR) ranges from 44-50, and my weight is 132 pounds. My ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
A cystatin C–based blood test may provide a more reliable way to monitor kidney function in children and young adults with SCD, a study found.
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results